NDT Pharmaceuticals Showcases Strategic Value of Good Salt(TM) Life Acquisition with Expanded Relationship with Norwegian Cruise Line
NDT Pharmaceuticals (OTC PINK: NDTP) announced a post-acquisition commercial milestone after acquiring Good Salt Life on September 5, 2025. Good Salt Life received an expanded order from Norwegian Cruise Line for 20 induction-charged disinfectant sprayers that deploy EPA-approved hypochlorous acid (HOCl) solutions fleetwide for communal areas and staterooms.
The release highlights Good Salt Life's vertically integrated biosafety ecosystem (hardware, EPA-approved chemistries, data protocols), claims hospital-grade disinfection using an electrolysis process, and positions NDT to address the $148 billion global biosafety market across hospitality, healthcare, and transportation.
NDT Pharmaceuticals (OTC PINK: NDTP) ha annunciato una pietra miliare commerciale post-acquisizione dopo aver acquisito Good Salt Life il 5 settembre 2025. Good Salt Life ha ricevuto un ordine ampliato da Norwegian Cruise Line per 20 nebulizzatori disinfettanti a induzione che dispongono di soluzioni di acido ipocloroso (HOCl) approvate dall'EPA, utilizzate su tutta la flotta per aree comuni e cabine.
Il comunicato evidenzia l'ecosistema di biosicurezza verticalmente integrato di Good Salt Life (hardware, chimiche approvate dall'EPA, protocolli dati), afferma una disinfezione di livello ospedaliero mediante un processo di elettrolisi e posiziona NDT per affrontare il mercato globale della biosicurezza da $148 miliardi nei settori ospitalità, sanità e trasporti.
NDT Pharmaceuticals (OTC PINK: NDTP) anunció un hito comercial posterior a la adquisición tras adquirir Good Salt Life el 5 de septiembre de 2025. Good Salt Life recibió un pedido ampliado de Norwegian Cruise Line por 20 pulverizadores desinfectantes cargados por inducción que despliegan soluciones de ácido hipocloroso (HOCl) aprobadas por la EPA en toda la flota para áreas comunes y camarotes.
El comunicado destaca el ecosistema de bioseguridad verticalmente integrado de Good Salt Life (hardware, químicas aprobadas por la EPA, protocolos de datos), afirma una desinfección de grado hospitalario mediante un proceso de electrólisis y posiciona a NDT para abordar el mercado global de bioseguridad de $148 mil millones en hospitalidad, salud y transporte.
NDT Pharmaceuticals (OTC PINK: NDTP)는 Good Salt Life를 2025년 9월 5일 인수한 후 인수 후 상업적 이정표를 발표했습니다. Good Salt Life는 Norwegian Cruise Line으로부터 선내 공용 공간과 객실에 EPA 승인 HOCl 용액을 배치하는 20개의 유도식 소독 분사기에 대한 확대 주문을 받았습니다.
보도자료는 Good Salt Life의 수직적으로 통합된 생물안전 생태계(하드웨어, EPA 승인 화학물질, 데이터 프로토콜)를 강조하고 전기분해 공정을 이용한 병원급 소독을 주장하며, NDT가 환대, 보건의료, 운송에 걸친 글로벌 생물안전 시장 1,480억 달러를 공략할 수 있음을 제시합니다.
NDT Pharmaceuticals (OTC PINK: NDTP) a annoncé une étape commerciale post-acquisition après l'acquisition de Good Salt Life le 5 septembre 2025. Good Salt Life a reçu une commande élargie de Norwegian Cruise Line pour 20 pulvérisateurs désinfectants à induction qui déploient des solutions d'acide hypochloreux (HOCl) approuvées par l'EPA dans toute la flotte pour les espaces communs et les cabines.
Le communiqué met en avant l'écosystème de biosécurité verticalement intégré de Good Salt Life (hardware, chimies approuvées par l'EPA, protocoles de données), affirme une désinfection de niveau hospitalier par un procédé d'électrolyse et positionne NDT pour adresser le marché mondial de la biosécurité, évalué à 1 480 milliards de dollars dans l'hôtellerie, les soins de santé et les transports.
NDT Pharmaceuticals (OTC PINK: NDTP) gab eine nach der Akquisition erzielte kommerzielle Meilenstein bekannt, nachdem sie Good Salt Life am 5. September 2025 übernommen hatten. Good Salt Life erhielt eine erweiterte Bestellung von Norwegian Cruise Line für 20 induktionsgeladene Desinfektionssprayer, die EPA- genehmigte Hypochlorous-Säure (HOCl)-Lösungen fleetsweit für Gemeinschaftsbereiche und Kabinen einsetzen.
Die Pressemitteilung hebt Good Salt Lifes vertikal integriertes Biosicherheits-Ökosystem (Hardware, EPA- genehmigte Chemistries, Datenprotokolle) hervor, behauptet eine hospital-grade Desinfektion mittels eines Elektrolyseprozesses und positioniert NDT, um den globalen Biosicherheitsmarkt von 1,48 Billionen US-Dollar im Bereich Gastgewerbe, Gesundheitswesen und Transport zu adressieren.
NDT Pharmaceuticals (OTC PINK: NDTP) أعلنت عن نقطة قياس تجاريّة ما بعد الاستحواذ بعد استحواذها على Good Salt Life في 5 سبتمبر 2025. تلقت Good Salt Life طلباً موسعاً من Norwegian Cruise Line لــ 20 رشاشاً مطهراً بتقنية الاستحثاث/التحفيز التي تستخدم محاليل حمض الهيبوكلوروسي HOCl المعتمدة من وكالة حماية البيئة EPA عبر الأسطول للمناطق المشتركة والكنب.
يبرز البيان الصحفي النظام البيئي الحيوي الأمني الرأسي التكامل لـ Good Salt Life (الأجهزة، الكيميائيات المعتمدة من EPA، بروتوكولات البيانات)، ويدعي تعقيماً بمستوى المستشفيات باستخدام عملية التحليل الكهربائي، ويضع NDT في موضع يتيح له التوجه إلى سوق الأمن الحيوي العالمي الذي تبلغ قيمته 1,480 مليار دولار عبر الضيافة والرعاية الصحية والنقل.
NDT Pharmaceuticals（OTC PINK: NDTP） 在于 2025年9月5日 收购 Good Salt Life 之后宣布了一项并购后商业里程碑。Good Salt Life 从 挪威邮轮公司 获得扩展订单，包含 20 台感应充电式消毒喷雾器，在整个舰队的公共区域和舱房中部署经 EPA 批准的次氯酸（HOCl）溶液。
新闻稿强调 Good Salt Life 的垂直整合生物安全生态系统（硬件、EPA 批准的化学药剂、数据协议），声称通过电解工艺实现医院级消毒，并将 NDT 定位为在酒店、医疗保健与交通等领域应对全球 1,480亿美元 的生物安全市场。
- Acquisition completed on 09/05/2025
- Order: 20 induction-charged sprayers from Norwegian Cruise Line
- Targets the $148 billion global biosafety market
- None.
ATHENS, GEORGIA / ACCESS Newswire / October 21, 2025 / NDT Pharmaceuticals Inc. (OTC PINK:NDTP), a company focused on advancing innovative consumer health and wellness solutions, today announced a major post-acquisition milestone with the expanded relationship between its subsidiary, Good Salt™ Life, Inc., and Norwegian Cruise Line (NCL).
Following NDT Pharmaceuticals' acquisition of Good Salt Life on September 5, 2025, the subsidiary has deepened its long-standing relationship with NCL, which has placed an order for 20 new induction-charged disinfectant sprayers from the Good Salt Life biosafety ecosystem. The advanced, portable units will deploy Good Salt Life's EPA-approved, eco-friendly hypochlorous acid (HOCl) solutions throughout communal areas and staterooms fleetwide, reinforcing NCL's leadership in passenger health and safety as the cruise industry enters peak cold and flu season.
"The decision by Norwegian Cruise Line to immediately expand its investment in Good Salt Life's technology is a powerful validation of the value proposition we saw in the acquisition," said Zach O'Shea, President and CEO of NDT Pharmaceuticals. "This transaction was not just about adding a new product line; it was about acquiring a proven ecosystem that delivers superior, sustainable solutions to major clients in high-value sectors like the cruise industry. Our commitment, and NCL's expanded order, directly addresses the growing demand for advanced, non-toxic infection control solutions."
Good Salt Life: Sustainable Technology for High-Value Markets
Headquartered in Athens, Georgia, Good Salt Life is a vertically integrated biosafety innovator combining proprietary hardware, EPA-approved chemistries, and data-driven infection-control protocols. Its newest induction-charged sprayers are engineered for maximum performance and portability, enabling NCL's sanitation teams to quickly disinfect large spaces using the company's signature non-toxic antimicrobial solution.
The sprayers utilize a proprietary electrolysis process that converts simple salt and water into hypochlorous acid (HOCl), a powerful, naturally occurring substance produced by the human body to combat infection. The result is hospital-grade disinfection without toxic chemicals, supporting continuous safety operations in high-density public environments.
"We are proud to see our technology and solutions continuing to set the benchmark for passenger health and safety at sea with a respected leader like Norwegian Cruise Line," added O'Shea. "The integration with NDT Pharmaceuticals provides the resources to accelerate innovation and expand the deployment of Good Salt Life's holistic safety solutions, including advanced sprayers and next-generation technologies like robotics and AI-driven automation."
Driving Immediate Value Post-Acquisition
The expanded NCL relationship underscores the synergy and commercial momentum already realized from the Good Salt Life acquisition. This integration has strengthened NDT Pharmaceuticals' position in the
About NDT Pharmaceuticals, Inc. (OTC PINK:NDTP)
NDT Pharmaceuticals, Inc. is a publicly traded company focused on advancing innovative consumer health and wellness solutions. Through its subsidiary, Good Salt Life, the Company has expanded its strategic direction into sustainable, science-driven products that promote healthier living. The Company is committed to building value through investments in sustainable, science-driven brands that protect people, pets, and the planet while aligning with growing consumer demand for eco-friendly and health-conscious alternatives.
About Good Salt™ Life, Inc.
Good Salt Life is dedicated to promoting vitality through eco-friendly, nature-derived products that support healthier living environments. With a focus on innovation and sustainability, the company offers safe and effective solutions for home, pet, personal care, and animal health. Through strategic partnerships, including collaborations in the B2B animal health sector, Good Salt Life continues to drive advancements that benefit both people and animals. For more information, visit www.goodsaltlife.com.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as "may," "might," "will," "intend," "should," "could," "can," "would," "continue," "expect," "believe," "anticipate," "estimate," "predict," "outlook," "potential," "plan," "seek," and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect the Company's current expectations and speak only as of the date of this release. Actual results may differ materially from the Company's current expectations. Except as required by law, the Company does not undertake any responsibility to revise or update any forward-looking statements.
Contact:
SOURCE: NDT Pharmaceuticals Inc.
View the original press release on ACCESS Newswire
FAQ
When did NDT Pharmaceuticals complete the Good Salt Life acquisition (NDTP)?
How many disinfectant sprayers did Norwegian Cruise Line order from Good Salt Life (NDTP)?
What disinfectant technology will NDTP's Good Salt Life supply to NCL?
How does the NCL order affect NDT Pharmaceuticals' market positioning (NDTP)?
Which sectors is NDT Pharmaceuticals targeting after the Good Salt Life acquisition (NDTP)?
